PE20201464A1 - Conjugados anticuerpo anti-cd40-farmaco - Google Patents

Conjugados anticuerpo anti-cd40-farmaco

Info

Publication number
PE20201464A1
PE20201464A1 PE2020000592A PE2020000592A PE20201464A1 PE 20201464 A1 PE20201464 A1 PE 20201464A1 PE 2020000592 A PE2020000592 A PE 2020000592A PE 2020000592 A PE2020000592 A PE 2020000592A PE 20201464 A1 PE20201464 A1 PE 20201464A1
Authority
PE
Peru
Prior art keywords
antibody conjugates
drug antibody
antibody
formula
drug conjugates
Prior art date
Application number
PE2020000592A
Other languages
English (en)
Inventor
Jason Z Oh
Michael J Mcpherson
Wendy Waegell
Shaughn H Bryant
Axel Hernandez Jr
Claire L Ihle
Christopher C Marvin
Olivia A Perng
Ling C Santora
Lu Wang
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of PE20201464A1 publication Critical patent/PE20201464A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente se proporcionan conjugados anticuerpo anti-CD40-farmaco que comprenden un radical de la Formula (I), en donde R1, R2 y R3 son como se definen en la presente. Ademas se proporcionan conjugados anticuerpo anti-CD40-farmaco de la Formula (II), en donde Z, R, AA1, AA2, AA3, m, p, q, n, w, R1, R2 y R3 son como se definen en la presente. Ademas se proporcionan composiciones farmaceuticas y kits de estas, y metodos para usarlos
PE2020000592A 2017-12-01 2018-11-29 Conjugados anticuerpo anti-cd40-farmaco PE20201464A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762593807P 2017-12-01 2017-12-01
US201762595045P 2017-12-05 2017-12-05
PCT/IB2018/059480 WO2019106608A1 (en) 2017-12-01 2018-11-29 Anti-cd40 antibody drug conjugates

Publications (1)

Publication Number Publication Date
PE20201464A1 true PE20201464A1 (es) 2020-12-17

Family

ID=66663861

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020000592A PE20201464A1 (es) 2017-12-01 2018-11-29 Conjugados anticuerpo anti-cd40-farmaco

Country Status (19)

Country Link
US (1) US20220265842A1 (es)
EP (1) EP3716982A4 (es)
JP (1) JP2021504430A (es)
KR (1) KR20200095493A (es)
CN (1) CN111465399A (es)
AU (1) AU2018374633A1 (es)
BR (1) BR112020010691A2 (es)
CA (1) CA3081559A1 (es)
CL (1) CL2020001442A1 (es)
CR (1) CR20200285A (es)
DO (1) DOP2020000119A (es)
EC (1) ECSP20034868A (es)
IL (1) IL274650A (es)
MX (1) MX2020005465A (es)
PE (1) PE20201464A1 (es)
PH (1) PH12020550551A1 (es)
RU (1) RU2020117156A (es)
SG (1) SG11202004865SA (es)
WO (1) WO2019106608A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220098315A1 (en) * 2019-01-11 2022-03-31 Novartis Ag Anti-cd40 antibodies for use in treatment of hidradenitis
CA3207416A1 (en) * 2021-02-04 2022-08-11 Lingjian ZHU Drug conjugate of glucocorticoid receptor agonist, and application thereof in medicine
TW202304462A (zh) * 2021-03-23 2023-02-01 美商美國禮來大藥廠 糖皮質素受體激動劑
AR125079A1 (es) 2021-03-23 2023-06-07 Lilly Co Eli Agonistas de receptores de glucocorticoides sustituidos con carboxi
WO2022268176A1 (zh) * 2021-06-24 2022-12-29 江苏先声药业有限公司 甾体类化合物、其药物组合物及其应用
WO2023025248A1 (zh) * 2021-08-26 2023-03-02 映恩生物制药(苏州)有限公司 一种甾体化合物及其缀合物
TW202327620A (zh) * 2021-09-14 2023-07-16 大陸商映恩生物製藥(蘇州)有限公司 一種抗炎症的化合物及其用途
JP2023184489A (ja) * 2022-06-16 2023-12-28 アッヴィ・バイオセラピューティクス・インコーポレイテッド 抗cd19抗体薬物コンジュゲート
WO2024020164A2 (en) 2022-07-21 2024-01-25 Firefly Bio, Inc. Glucocorticoid receptor agonists and conjugates thereof
WO2024064779A1 (en) * 2022-09-22 2024-03-28 Eli Lilly And Company Glucocorticoid receptor agonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010005861A (es) * 2007-11-30 2010-06-11 Pfizer Ltd Agonistas novedosos de los receptores de glucocorticoides.
JP2011507878A (ja) * 2007-12-21 2011-03-10 シェーリング コーポレイション C20−c21置換グルココルチコイド受容体アゴニスト
SG194701A1 (en) * 2011-04-29 2013-12-30 Apexigen Inc Anti-cd40 antibodies and methods of use
GB201309807D0 (en) * 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
EP3125943A4 (en) * 2014-04-04 2017-12-06 Merck Sharp & Dohme Corp. Phosphate based linkers for intracellular delivery of drug conjugates
UY36692A (es) * 2015-05-29 2016-12-30 Abbvie Inc Anticuerpos anti-cd40 y usos de los mismos

Also Published As

Publication number Publication date
CA3081559A1 (en) 2019-06-06
BR112020010691A2 (pt) 2020-11-10
EP3716982A4 (en) 2021-08-11
ECSP20034868A (es) 2020-08-31
DOP2020000119A (es) 2020-08-31
MX2020005465A (es) 2020-09-07
CR20200285A (es) 2020-09-04
IL274650A (en) 2020-06-30
EP3716982A1 (en) 2020-10-07
AU2018374633A1 (en) 2020-05-21
JP2021504430A (ja) 2021-02-15
PH12020550551A1 (en) 2021-03-22
CL2020001442A1 (es) 2020-09-11
KR20200095493A (ko) 2020-08-10
CN111465399A (zh) 2020-07-28
SG11202004865SA (en) 2020-06-29
RU2020117156A (ru) 2022-01-04
US20220265842A1 (en) 2022-08-25
WO2019106608A1 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
ECSP20034868A (es) Conjugados anticuerpo anti-cd40-fármaco
CL2021001706A1 (es) Receptores de antígenos quiméricos dirigidos a bcma y métodos de uso de estos (divisional de solicitud no. 201900326)
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
CL2020000263A1 (es) Conjugado de anticuerpo monoclonal contra bcma-fármaco.
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
BR112019007612A2 (pt) conjugados de pirrolobenzodiazepina
CL2019001740A1 (es) Novedoso conjugado de amanitina.
EA201791550A1 (ru) Димеры бензодиазепинов, их конъюгаты и способы их получения и применения
CO2017004782A2 (es) Conjugados de anticuerpo- farmaco
CO2019009373A2 (es) Compuestos heterocíclicos útiles como inhibidores duales de atx/ca.
UY35915A (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
CO6680688A2 (es) Anticuerpos para el receptor del factor de crecimiento epidérmico 3(her3)
AR057237A1 (es) Metodos y composiciones para actuar sobre la poliubiquitina
DOP2017000202A (es) Desacetoxitubulisina h y análogos de esta
CR20190268A (es) Nuevos deribados de isoxazolil éter como pam de gaba a alfa5
BR112021015477A2 (pt) Anticorpos anti-cd228 e conjugados anticorpo-fármaco
BR112018075630A2 (pt) anticorpos anti-cd98 e conjugados de fármaco de anticorpo
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
CO2020003020A2 (es) Herbicidas de carboxilato de piridina y pirimidina y métodos para su uso
CL2021001308A1 (es) Derivados de bis-octahidrofenantreno carboxamida y conjugados de proteína de los mismos para su uso como agonistas de lxr.
ECSP21068097A (es) Anticuerpos claudina 6 y usos de los mismos
CL2020001062A1 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos.
CL2023000894A1 (es) Compuestos de heteroarilo fusionados y su uso como inhibidores de camkii
UY38759A (es) Tienilhidroxiisoxazolinas y derivados de las mismas
BR112018012884A2 (pt) novos anticorpos anti-mmp16 e métodos de uso